Latest Biomarker Stories

[ Watch the Video: Gene That Leads To Hearing Loss ] Connie K. Ho for redOrbit.com – Your Universe Online Researchers from the University of South Florida (USF) recently identified a gene related to hearing loss in older Americans. 30 million individuals in the U.S. suffer from hearing loss and the new findings will assist in the development of preventive efforts for this particular population. The discovery of a genetic biomarker for age-related hearing loss is nine years in the...

Analysis of specific biomarkers in a cerebrospinal fluid sample can differentiate patients with Alzheimer's disease from those with other types of dementia. The method, which is being studied by researchers at Sahlgrenska Academy, may eventually permit earlier detection of Alzheimer's disease. Due to the similarity of the symptoms, differentiating patients with Alzheimer's from those with other types of dementia – or patients with Parkinsondisease from those with other motor disorders...

Collaborators at Cottage Health System and UC Santa Barbara's College of Engineering have identified biomarkers that may yield a revolutionary diagnostic test for pre-eclampsia, a complex and potentially life-threatening hypertensive condition affecting 5% of pregnancies worldwide. The most common dangerous complication of pregnancy, pre-eclampsia is potentially fatal and often mimics or is confused with other pregnancy-related conditions—such as swelling, gastric pain, and high blood...

SUNNYVALE, Calif., Oct. 11, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptotis therapeutic protein MANF , today announced that it has acquired an exclusive option to license the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, LLC. Under the terms of the...

CAMBRIDGE, Mass., Oct. 10, 2012 /PRNewswire/ -- DART Therapeutics, LLC, an innovative, new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), announced today the successful completion of a study to evaluate a promising new biomarker for DMD. The biomarker, electrical impedance myography (EIM), is a non-invasive and simple-to-use technique that allows the operator to measure the health of a muscle and track its changes over time. The...

Ignyta’s vision is to kindle the development and usage of the most accurate molecular diagnostic tests and precisely targeted therapeutics in autoimmune diseases (AID) and to extinguish AID through earlier, more enlightened diagnosis and treatment of patients worldwide. San Diego, CA (PRWEB) October 09, 2012 NexDx, Inc. announced today that it has changed its name to Ignyta, Inc. The name change reflects the San Diego based biotechnology company’s broader commitment to catalyzing the...

CARLSBAD, Calif., Oct. 8, 2012 /PRNewswire/ -- Life Technologies (NASDAQ: LIFE) today announced the acquisition of Compendia Bioscience, a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. Its deep oncology expertise and high-value, proprietary assets enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR and...

Scientists from the Florida campus of The Scripps Research Institute have developed a novel technology that can identify, in animal models, potential biomarkers of ulcerative colitis, a type of inflammatory bowel disease that affects the lining of the colon. The study was published October 3, 2012, in the Journal of the American Chemical Society. The new research focuses on the protein arginine deiminases (PAD), which have been implicated in a number of diseases, including cancer,...

Identified biomarkers may enable early diagnosis of malignant mesothelioma, a cancer linked to prolonged asbestos exposure Researchers have discovered a panel of 13 blood proteins that may be effective biomarkers to detect malignant mesothelioma, according to a study published Oct. 3 in the open access journal PLOS ONE by Rachel Ostroff from the company SomaLogic, which developed the new test, and colleagues at other institutions. Malignant mesothelioma is a rare, aggressive form of...

MANSFIELD, Mass., Oct. 3, 2012 /PRNewswire/ -- PrimeraDx, Inc. announced today that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012. FierceMedicalDevices Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year's winners based on their top management teams, notable financial backing, and promising...